Key result
Applying criteria using values above the 99th percentile with the newer TnI-Ultra assay and a 20% change identified 66 additional episodes of acute myocardial injury among 284 patients.
Answers are grounded in this paper and cite their sources.
This editorial discusses the implications of using contemporary versus older cardiac troponin assays for diagnosing acute myocardial infarction, highlighting the need for refined criteria.
An article in the December 2008 issue of the Journal 1 raises a variety of issues that are key to the implementation of the universal definition of myocardial infarction (AMI).2–4 The group from Catalonia, Spain, evaluated a strategy using a contemporary, not an ultrasensitive, cardiac troponin (cTn) assay from Siemens Healthcare Diagnostics (Tarrytown, NY) in 284 consecutive patients. They applied criteria for AMI using the old iteration of the Bayer assay (Bayer, Tarrytown, NY) and a set of criteria using values above the 99th percentile with the newer, more sensitive TnI-Ultra assay in association with a 20% change. They reported an ability to diagnose 66 additional episodes of acute myocardial injury with this approach. This is slightly more than half of the 109 times that they observed values above the 99th percentile. They suggest that this approach increased their specificity for diagnosing acute cardiac injury. Furthermore, they thought clinically that more than half of the patients who might have been diagnosed as meeting criteria for acute cardiac injury had some other serious medical complications such as heart failure and nonanginal chest pain to explain the elevations rather than AMI. Irrespective, apparently, of the diagnosis, these patients were at increased risk during follow-up. How these diagnoses were quality assured is unclear, and a receiver operating characteristic curve analysis would also have helped to more clearly characterize the phenomena reported. One of the benefits of this sort of an analysis is that it helps to refine how we use cTn assays. It amplifies certain critical issues that are important and leaves open several issues that are worthy of discussion. The first issue has to do with the designation of the assay used as an “ultrasensitive” cTn assay. The Siemens cTnI-Ultra assay is, in our view, a contemporary assay with …
No takes yet. Share an insight, caveat, or question.
Jaffe et al. (2008) conducted an editorial in Myocardial infarction (n=284). TnI-Ultra assay vs. Old iteration of the Bayer assay was evaluated on Diagnosis of acute myocardial injury. Applying criteria using values above the 99th percentile with the newer TnI-Ultra assay and a 20% change identified 66 additional episodes of acute myocardial injury among 284 patients.
Synapse has enriched 10 related papers. Consider them for comparative context: